Ian Estepan | Vice President, Chief of Staff and Corporate Affairs |
Douglas Ingram | President and Chief Executive Officer |
Sandy Mahatme | Executive Vice President, Chief Financial Officer and Chief Business Officer |
Bo Cumbo | Senior Vice President and Chief Commercial Officer |
Gilmore O'Neill | Senior VP of R&D and Chief Medical Officer |
Louise Rodino-Klapac | Vice President, Gene Therapy |
Brian Skorney | Baird |
Tazeen Ahmad | Bank of America |
Alethia Young | Cantor Fitzgerald |
Christopher Marai | Nomura |
Ritu Baral | Cowen |
Danielle Brill | Piper Jaffray |
Gena Wang | Barclays |
Shawn Egan | Citi |
Tim Chiang | BTIG |
Vincent Chen | Bernstein |
Hartaj Singh | Oppenheimer & Company |
Liisa Bayko | JMP Securities |
Yun Zhong | Janney |
Good day, ladies and gentlemen, and welcome to the Sarepta Therapeutics Fourth Quarter and Full Year 2018 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder today's program is being recorded. And now, I'd like to introduce your host for today's program, Ian Estepan, Vice President, Chief of Staff and Corporate Affairs.